Search results
Showing 1151 to 1200 of 2053 results for work
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
In development Reference number: GID-TA11433 Expected publication date: TBC
Discontinued Reference number: GID-SGWAVE0702
Discontinued Reference number: GID-SGWAVE0761
Discontinued Reference number: GID-SGWAVE0700
Discontinued Reference number: GID-TAG526
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Discontinued Reference number: GID-TA10171
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued Reference number: GID-TA10193
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued Reference number: GID-TA10480
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Discontinued Reference number: GID-TA10536
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued Reference number: GID-TA10539
Discontinued Reference number: GID-TA10628
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued Reference number: GID-TAG321
Discontinued Reference number: GID-TA11026
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Discontinued Reference number: GID-TA11000
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Discontinued Reference number: GID-TA11264
Discontinued Reference number: GID-TA10365
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
Discontinued Reference number: GID-TA10923
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Discontinued Reference number: GID-TA10851
Discontinued Reference number: GID-SGWAVE0762
Discontinued Reference number: GID-SGWAVE0701
Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.
View recommendations for HTG689Show all sections
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2 (placeholder): CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections
This quality standard covers managing acute painful episodes of sickle cell disease in hospital. It includes pain relief and care for children, young people and adults, from presentation in hospital until discharge. It describes high-quality care in priority areas for improvement.
View quality statements for QS58Show all sections
Sections for QS58
- Quality statements
- Quality statement 1: Timely assessment and analgesia
- Quality statement 2: Regular assessment of pain relief
- Quality statement 3: Strong opioids and monitoring
- Quality statement 4: Acute complications
- Quality statement 5: Protocols and specialist support
- Quality statement 6: Discharge information
- Update information
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development Reference number: GID-TA10779 Expected publication date: TBC
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
In development Reference number: GID-TA10843 Expected publication date: TBC
Discontinued Reference number: GID-TA10698
Discontinued Reference number: GID-TA10737
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Discontinued Reference number: GID-TA10763
Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]
Discontinued Reference number: GID-TAG337
Discontinued Reference number: GID-TA10591
Discontinued Reference number: GID-TAG427
Abicipar pegol for treating wet age-related macular degeneration [ID1533]
In development Reference number: GID-TA10511 Expected publication date: TBC
Discontinued Reference number: GID-TA10310
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
Discontinued Reference number: GID-TA10633
Discontinued Reference number: GID-TA10697
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Discontinued Reference number: GID-TAG410
Discontinued Reference number: GID-TA10996
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Discontinued Reference number: GID-HST10019
Discontinued Reference number: GID-QS10108
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013